John Crowley, chairman and former CEO of Amicus Therapeutics, joins the show to discuss the strides the biotech industry has made in therapies for rare genetic diseases and the industry landscape going forward. (This interview originally aired as part of Wharton Business Daily’s Business of Healthcare special.)
Looking for more insights?
Sign up to stay informed about our latest article releases.